These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 25437464)

  • 21. GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.
    Jespersen MJ; Knop FK; Christensen M
    Expert Opin Drug Metab Toxicol; 2013 Jan; 9(1):17-29. PubMed ID: 23094590
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects.
    Drab SR
    Pharmacotherapy; 2010 Jun; 30(6):609-24. PubMed ID: 20500049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.
    van Genugten RE; van Raalte DH; Diamant M
    Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S26-34. PubMed ID: 20115929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials.
    Monami M; Dicembrini I; Nardini C; Fiordelli I; Mannucci E
    Diabetes Obes Metab; 2014 Jan; 16(1):38-47. PubMed ID: 23829656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adverse Effects of GLP-1 Receptor Agonists.
    Filippatos TD; Panagiotopoulou TV; Elisaf MS
    Rev Diabet Stud; 2014; 11(3-4):202-30. PubMed ID: 26177483
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials.
    Mabilleau G; Mieczkowska A; Chappard D
    J Diabetes; 2014 May; 6(3):260-6. PubMed ID: 24164867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Characteristics and types of GLP-1 receptor agonists. An opportunity for individualized therapy].
    Jódar E
    Med Clin (Barc); 2014 Sep; 143 Suppl 2():12-7. PubMed ID: 25437460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GLP-1 receptor agonists: effects on cardiovascular risk reduction.
    Lorber D
    Cardiovasc Ther; 2013 Aug; 31(4):238-49. PubMed ID: 23865382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide.
    Vilsbøll T; Garber AJ
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():41-9. PubMed ID: 22405268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging GLP-1 receptor agonists.
    Lund A; Knop FK; Vilsbøll T
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):607-18. PubMed ID: 21905764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The new antidiabetic agents in the firing line.... safety reasons or witch hunt?].
    Nicolau Ramis J; Masmiquel Comas L
    Endocrinol Nutr; 2012 Jan; 59(1):1-8. PubMed ID: 22177885
    [No Abstract]   [Full Text] [Related]  

  • 34. On-target effects of GLP-1 receptor agonists on thyroid C-cells in rats and mice.
    Rosol TJ
    Toxicol Pathol; 2013 Feb; 41(2):303-9. PubMed ID: 23471186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular safety and glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: a pairwise and network meta-analysis.
    Sun F; Yu K; Wu S; Zhang Y; Yang Z; Shi L; Ji L; Zhan S
    Diabetes Res Clin Pract; 2012 Dec; 98(3):386-95. PubMed ID: 23020934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues.
    Raccah D
    Expert Opin Drug Saf; 2017 Feb; 16(2):227-236. PubMed ID: 27924636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Minireview: update on incretin biology: focus on glucagon-like peptide-1.
    Brubaker PL
    Endocrinology; 2010 May; 151(5):1984-9. PubMed ID: 20305008
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The future of incretin-based therapy: novel avenues--novel targets.
    Ahrén B
    Diabetes Obes Metab; 2011 Oct; 13 Suppl 1():158-66. PubMed ID: 21824270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An overview of incretin clinical trials.
    Garber AJ; Spann SJ
    J Fam Pract; 2008 Sep; 57(9 Suppl):S10-8. PubMed ID: 18786339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Innovations in the treatment of type 2 diabetes mellitus: use of incretins].
    Dedov II; Shestakova MV; Sukhareva OIu
    Ter Arkh; 2010; 82(10):5-10. PubMed ID: 21341455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.